Literature DB >> 11817326

T cell immunotherapeutic populations control viral infections in bone marrow transplant recipients.

K S Slobod1, E Benaim, L Woodruff, S Nooner, J Houston, M Holladay, T Lockey, J L Hurwitz.   

Abstract

Immunotherapies designed to prevent infection serve as an increasingly important adjunct to bone marrow transplantation (BMT). T cell immunotherapies are particularly useful for the control of virus infections, provided that T cell populations are free of graft-vs-host (GVH) activity. In this review, we describe positive and negative selection methods with which donor T cell populations devoid of GVH activity can be prepared for transfer to the immunodeficient BMT recipient. The support of patients with T cell immunotherapies may ultimately revolutionize BMT, elevating the procedure from a salvage to a front-line treatment strategy for otherwise fatal disorders.

Entities:  

Mesh:

Year:  2001        PMID: 11817326     DOI: 10.1385/IR:24:3:289

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  47 in total

1.  Estimates of cytotoxic T-lymphocyte precursor frequencies against HLA class I antigens in responder-stimulator pairs with a negative mixed lymphocyte culture reaction.

Authors:  A S Slavcev; B S Breur-Vriesendorp; P Ivanyi
Journal:  Hum Immunol       Date:  1995-10       Impact factor: 2.850

Review 2.  Adoptive immunotherapy for Epstein-Barr virus-related lymphoma.

Authors:  C A Smith; C Y Ng; S K Loftin; C Li; H E Heslop; M K Brenner; C M Rooney
Journal:  Leuk Lymphoma       Date:  1996-10

Review 3.  Reconstruction of the haemopoietic and immune systems after marrow transplantation.

Authors:  K Atkinson
Journal:  Bone Marrow Transplant       Date:  1990-04       Impact factor: 5.483

4.  Transplantation of anergic histoincompatible bone marrow allografts.

Authors:  E C Guinan; V A Boussiotis; D Neuberg; L L Brennan; N Hirano; L M Nadler; J G Gribben
Journal:  N Engl J Med       Date:  1999-06-03       Impact factor: 91.245

5.  Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens.

Authors:  D Niederwieser; A Grassegger; J Auböck; M Herold; D Nachbaur; A Rosenmayr; A Gächter; W Nussbaumer; S Gaggl; M Ritter
Journal:  Blood       Date:  1993-04-15       Impact factor: 22.113

Review 6.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.

Authors:  P D Greenberg
Journal:  Adv Immunol       Date:  1991       Impact factor: 3.543

7.  Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer.

Authors:  F Mavilio; G Ferrari; S Rossini; N Nobili; C Bonini; G Casorati; C Traversari; C Bordignon
Journal:  Blood       Date:  1994-04-01       Impact factor: 22.113

8.  Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro.

Authors:  C A Smith; L S Woodruff; G R Kitchingman; C M Rooney
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.

Authors:  H E Heslop; C Y Ng; C Li; C A Smith; S K Loftin; R A Krance; M K Brenner; C M Rooney
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

10.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.

Authors:  C Bonini; G Ferrari; S Verzeletti; P Servida; E Zappone; L Ruggieri; M Ponzoni; S Rossini; F Mavilio; C Traversari; C Bordignon
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728

View more
  2 in total

Review 1.  How I treat EBV lymphoproliferation.

Authors:  Helen E Heslop
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

2.  Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment.

Authors:  Sanam Shahid; Susan E Prockop
Journal:  Cancer Drug Resist       Date:  2021-06-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.